Activated partial thromboplastin time (APTT) and anti-factor Xa activity are commonly used to monitor anticoagulant effects, but both have limitations. APTT reflects only part of the intrinsic coagulation pathway, can be affected by inflammation, pregnancy, kidney disease, and lupus anticoagulant, and cannot be used to monitor LMWH. Anti-Xa testing measures factor Xa inhibition alone rather than the final inhibition of thrombus formation. Neither test captures the combined contribution of thrombin, fibrinogen, and platelets to that final outcome. Abnormalities in these components can alter clot formation and make the same drug dose functionally excessive or insufficient in different patients.

Automated thromboelastography (ATEG) uses a clot-based assay to follow the process from coagulation initiation to clot formation in whole blood. By observing the final clotting outcome, it is intended to make the antithrombotic effects of anticoagulants directly visible and support monitoring in the prevention and treatment of thrombotic disease.

01

Heparin Therapy and the Challenge of Balancing Thrombosis and Bleeding

A thrombus can be compared to sediment obstructing a river. Myocardial infarction, cerebral infarction, lower-limb venous thrombosis, and vascular occlusion after flap surgery all involve abnormal thrombus formation. Heparin and LMWH bind to antithrombin III (ATIII), inhibit key coagulation factors, and thereby help prevent thrombus formation.

Coagulation is an interconnected reaction system: coagulation factors, fibrin, and platelets act together to produce a stable clot. Conventional tests generally measure selected indicators or biomarkers. In the river analogy, they identify sediment at one point and the possibility of obstruction without showing the severity of the final obstruction along the entire channel. This can lead to errors when assessing how effectively flow has been restored.

Insufficient Dosing and Recurrent Thrombosis

Inadequate anticoagulation allows hypercoagulability to persist. Stents, flaps, and lower-limb vessels may become occluded, leading to tissue or limb necrosis and, in severe cases, life-threatening cerebral or myocardial infarction.

Excessive Dosing and Increased Bleeding Risk

Excess heparin or LMWH can markedly weaken clot formation and cause extensive subcutaneous bruising, gastrointestinal bleeding, or intracranial hemorrhage. Dialysis and postoperative patients face particular risks.

Interference in Special Patient Populations

Kidney disease, inflammation, advanced age, obesity, pregnancy, and viral infection can create distinctive coagulation conditions. The source article describes these conditions as potential confounders of APTT or anti-Xa results, complicating precise dose adjustment.

Heparin resistance presents a further challenge. Conventional indicators may appear to meet their targets during standard-dose heparin therapy, while platelet release of platelet factor 4 (PF4) neutralizes its anticoagulant effect and hypercoagulability persists. The article presents clot-based thromboelastography as a way to observe the final clotting outcome and address the limited perspective of individual conventional indicators.

02

How the ATEG Clot-Based Assay Assesses Heparin and LMWH Effects

ATEG uses whole blood to simulate physiological coagulation conditions. Its integrated modules provide temperature control, automatic sampling, mixing, incubation, and mechanical measurement. Standardized testing is performed in parallel in an ordinary test cup and a heparin-control cup. The ordinary cup retains the heparin present in the sample; the comparison cup breaks down and removes heparin or LMWH. Comparing the two curves and their parameters is used to quantify the drugs’ effects on clot formation and strength.

Four core curve parameters describe the clotting response:

R — Coagulation Reaction Time

Inhibition of relevant coagulation factors by heparin or LMWH prolongs R. The article interprets a longer R as a stronger antithrombotic effect and a difference between the R values in the two cups as evidence of heparin or LMWH in the sample.

K and the α Angle — Clot Development

K and the α angle reflect the speed of fibrin cross-linking and clot development. As heparin or LMWH slows clot formation, K increases and the α angle decreases.

MA — Maximum Amplitude

MA represents overall clot strength. The article relates a reduction in MA to suppression of platelet procoagulant activity by heparin or LMWH and a resulting reduction in clot-forming capacity.

The clot-based assay follows the coagulation sequence while incorporating contributions from coagulation factors, fibrin, and platelets. It evaluates their combined final response to anticoagulation rather than changes in a single factor or selected biomarkers. Whole-blood testing can provide a complete report rapidly in emergency, intraoperative, and dialysis bedside settings, addressing the time and coverage limitations described for anti-Xa and APTT testing.

03

ATEG Testing Considerations

01

A Broader View of the Final Clotting Outcome

Conventional tests capture selected stages of coagulation, whereas ATEG follows the transition of blood from a liquid to a solid clot. The article describes this as a way to assess the antithrombotic effects of heparin or LMWH even when heparin resistance or endogenous heparin-like substances are present. For example, in unexplained APTT prolongation, comparison testing is presented as a means of distinguishing coagulation factor deficiency from interference by heparin-like substances.

02

Monitoring in Special Patient Populations

APTT cannot be used to monitor LMWH. The article describes potential limitations of anti-Xa results in patients with kidney disease, infection, cancer, pregnancy, or exposure to certain traditional Chinese medicines,. It discusses ATEG measurements in these settings. It proposes use in dialysis, postoperative care, thrombolysis, flap reconstruction, and amniotic fluid embolism. In severe viral illness, ATEG may reveal hypercoagulability despite prolonged APTT and support timely adjustment of anticoagulation.

03

Automated Rapid Testing for Emergency and Bedside Care

Automatic sampling, incubation, and reading standardize the workflow and reduce manual error. During major bleeding in critically ill patients, sudden intraoperative oozing, or dialysis anticoagulation monitoring, rapid parameter output can support prompt heparin dose adjustment or protamine administration to neutralize residual heparin.

04

Clinical Applications Across the Course of Thrombotic Disease

Hemodialysis — Managing Bleeding and Circuit Clotting

Dialysis commonly uses LMWH to prevent clotting in the extracorporeal circuit. Dose control is important: too little anticoagulation can obstruct the circuit and impair dialysis, whereas too much can cause persistent bleeding at the puncture site afterward.

Monitoring R and MA with ATEG can support individualized heparin or LMWH dosing. Testing after dialysis can also assess residual drug effects and guide neutralization, with the aim of reducing post-dialysis bleeding and circuit-clotting complications.

Perioperative Care — Flap, Orthopedic, and Cardiac Surgery

Oral and maxillofacial flap reconstruction, hip and knee replacement, and cardiac procedures involving cardiopulmonary bypass are settings in which heparin or LMWH is used to prevent thrombosis, including thrombosis at vascular anastomoses. With fixed-dose regimens, some patients develop flap ischemia and necrosis, while others experience persistent wound oozing.

The article discusses using ATEG measurements to assess changes in coagulation during LMWH therapy. It also describes comparing test results after cardiopulmonary bypass to evaluate residual heparin effects.

Cardiovascular and Cerebrovascular Disease and Thrombolysis

The source discusses anticoagulation with heparin or LMWH in the care of patients with acute cerebral infarction undergoing intravenous thrombolysis, myocardial infarction, or deep vein thrombosis. Coagulation status may fluctuate substantially after thrombolysis, and conventional indicators may not predict recurrent thrombosis or intracranial bleeding.

By tracking changes in clot strength in real time, ATEG is presented as a way to assess anticoagulant effects dynamically and support dose adjustment, balancing recurrent thrombosis against bleeding risk for both short- and long-term benefit.

Early Assessment in Kidney Disease, Cancer, and Pregnancy

Nephrotic syndrome, malignancy, and pregnancy are associated with a tendency toward spontaneous thrombosis, for which prophylactic LMWH may be used. Large individual differences in coagulation can produce substantially different responses to the same fixed dose.

ATEG is described as a means of identifying hypercoagulability early, quantifying inhibition by heparin or LMWH, and developing individualized prevention regimens. The article also discusses measuring coagulation changes in critical illness involving amniotic fluid embolism.

05

Additional Diagnostic Value in Complex Clinical Scenarios

Beyond routine anticoagulation monitoring, the article describes several difficult clinical situations in which the clot-based ATEG assay may provide additional information:

Endogenous Heparin or Heparin-Like Substances

When APTT is prolonged for an unexplained reason and the cause of bleeding is unclear, the ATEG heparin test is presented as a way to identify and quantify heparin-like effects and support targeted treatment.

Assessment of Heparin Resistance

Some patients remain hypercoagulable despite apparently adequate heparin dosing. Platelet-derived PF4 can neutralize heparin or LMWH. ATEG may show only mild R prolongation together with elevated MA and high clot strength, suggesting an insufficient drug effect. Quantitative parameters can then support timely changes in the anticoagulation regimen.

Coagulation Disturbances in Severe Infection

Patients with COVID-19 or severe infection may have prolonged APTT while ATEG shows high clot strength and a hypercoagulable tendency. The article interprets this pattern as possible platelet overactivation or other effects counteracting anticoagulation, calling for an effective treatment strategy instead of uninformed adjustment of heparin or LMWH dosing.

Combination Therapy, Synergy, Antagonism, and Bridging

Prevention and treatment of thrombosis often require two or more drugs, such as an anticoagulant combined with an antiplatelet agent. ATEG is presented as a means of measuring the resulting antithrombotic effect and supplying baseline parameters for combination therapy, with the aim of avoiding adverse events.

During drug bridging, the article proposes comparing the antithrombotic effects of the current anticoagulant and the bridging agent to identify equivalent effects. The intended result is a stable transition in anticoagulant activity between regimens, offering a new approach to bridging.

06

Toward Standardized Monitoring and Individualized Anticoagulation

Individualized heparin and LMWH therapy is an important direction in precision medicine. The intended outcome of anticoagulation is inhibition of thrombus formation, which results from complex interactions among coagulation factors and cellular components in whole blood. The article argues that selected factors or biomarkers alone cannot fully meet the clinical need to assess that outcome. It presents ATEG as a rapid bedside method that simulates physiological coagulation and provides a multidimensional assessment of final clot strength.

Future development is expected to include standardized operating procedures and disease-specific reference intervals for monitoring antithrombotic treatment. Another proposed direction combines ATEG with conventional coagulation testing and imaging: ATEG assesses systemic hypercoagulability or hypocoagulability, while ultrasound or CT locates thrombi. Together, these methods could support early screening, precise dose adjustment, local drug treatment, and prognosis assessment.

Because thrombi have a gel-like structure, the article also proposes developing quantitative ATE-AC parameters describing the antithrombotic effects of anticoagulants. The aim is standardized monitoring across heparin, LMWH, warfarin, newer oral anticoagulants including dabigatran etexilate, and antiplatelet drugs, while building a reference database for clinical antithrombotic treatment and AI-assisted diagnosis.

07

Conclusion

Thrombotic disease continues to cause substantial mortality and disability, and antithrombotic medications are increasingly used. Assessing an individual patient’s actual response is essential to prevention and treatment. A central difficulty in heparin and LMWH therapy is balancing efficacy and safety when dose decisions depend heavily on experience. APTT, anti-Xa activity, and thrombotic biomarkers measure selected aspects of a complex pathophysiological process and are subject to confounding influences, leaving clinicians without a direct view of the final antithrombotic outcome.

The article presents whole-blood ATEG as an approach to following the coagulation process and directly quantifying the overall inhibitory effects of heparin-based therapy on clot formation. Its proposed applications span preoperative prevention, intraoperative monitoring, postoperative reassessment, and critical care, aiming both to warn of thrombosis risk and to avoid severe bleeding from excessive medication.

As a testing platform for thrombotic disease prevention and individualized anticoagulant monitoring, ATEG is intended to support a shift from fixed dosing toward patient-specific, effective anticoagulation and antithrombotic care.